Does the DRD2-Taq1 A polymorphism influence treatment response to bupropion hydrochloride for reduction of the nicotine withdrawal syndrome?

Sean P. David, Raymond Niaura, George D. Papandonatos, William G. Shadel, Gary J. Burkholder, Dana M. Britt, Amy Day, Jeffrey Stumpff, Kent Hutchison, Michael Murphy, Elaine Johnstone, Siân Elin Griffiths, Robert T. Walton

Research output: Contribution to journalArticlepeer-review

Fingerprint Dive into the research topics of 'Does the DRD2-Taq1 A polymorphism influence treatment response to bupropion hydrochloride for reduction of the nicotine withdrawal syndrome?'. Together they form a unique fingerprint.

Medicine & Life Sciences